Mikael Dolsten isn’t the only one moving on from Pfizer; Lilly names interim finance chief
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
After more than three decades at Neurocrine, CEO Kevin Gorman will retire later this year, handing the reins of the $13 billion neuroscience drugmaker over
→ Jean-Paul Clozel is ready to pass the torch at his Actelion follow-up Idorsia, but he doesn’t want to walk away from the company altogether.
Jim Burns was looking for his next post after his latest venture in biotech, a gene therapy startup known as Locanabio, shut down “due to
Lykos Therapeutics is on a journey to get the first MDMA-assisted PTSD therapy approved by the FDA, and the biotech has tapped two new leaders
→ Lexicon Pharmaceuticals CEO Lonnel Coats will retire July 7, 10 years to the day after accepting the job. Lexicon overcame numerous regulatory obstacles with